Effect of omega 3 fatty acids supplement on inflamatory factor ( IL-1β, IL-6, TNF-α, IL-10) and lipid profile of prakinson disease.

1- Determination and comparison of the effect of omega-3 fatty acids and placebo on inflammatory factors (TNF-α, IL-1β and IL-6) and anti-inflammatory agent (IL-10) in Parkinson's patients. 2- Determination and comparison of the effects of omega-3 fatty acids and placebo on lipid profiles (HDL, LDL, and TG) in Parkinson's patients. 3- Determination and comparison of the effect of omega-3 fatty acids on body mass index and body fat percentage in patients with Parkinson's disease.

Clinical trial with community-based and pragmatic control group, with parallel, double-blind, randomized,

Patients will be selected from the Neurology Clinic of Imam Reza Hospital. Diagnosis is a neurologist's opinion. The goals and method of the study will be explained to the patients and, after obtaining written informed consent, all samples fill out the demographic information form. They are not asked to change their lifestyle during the course of the study, and continue their daily habits and exercise and previous diet.Each patient will be taken from the right arm in the morning after a 12-hour fasting, centrifuge, and stored at -80 ° C until the analysis is performed. The body composition of the patients will be measured by BIA. Receipt of the data was done by a questionnaire and the MNA questionnaire. The data will be analyzed in terms of energy intake and fatty acid by N4 software. Physical activity evaluation questionnaire (RAPA) will be used to assess the physical activity of patients

44 patients aged 50-70 who meet the criteria for entry and exit criteria, withdrawal criteria: unwillingness to cooperate, patients who had already taken Omega-3 (6 months ago), patients with depression or Psychosis, or other inflammatory disease, patients who can not use supplementation due to digestive problems or allergic reactions. People who smoke and drink alcohol. Entry criteria: Those with a neurologist who have Parkinson's diagnosis (except for patients with stage 4 and 5 disease) and aged 50-70 years, do not use aspirin or anticoagulant, or statin

Twenty-two individuals in the intervention group (including two daily omega-3 capsules of EPA: 180mg and DHA of 120mg taken from the Zahravi Pharmaceuticals Company) and 22 patients in the placebo group (two capsules per day, the combination of which Of soybean oil and will be supplied by Zahravi Pharmaceutical Company).

Supplementation of omega-3 fatty acids on serum inflammatory factors (TNF-α, IL-1β and IL-6) and anti-inflammatory agent (IL-10); lipid levels (HDL, LDL and TG); body mass index and percentage The fat affects patients with Parkinson's disease.

Simple randomization

In this study, participants randomly divided into omega-3 and placebo groups, and patients are unaware of being given placebo or omega-3. The doctor is unaware of which omega-3 patients and which placebo are receiving, and the investigator who is responsible for collecting data and analyzing the data is unaware of which patients received placebo and which omega-3s

Publish primary and raw results of samples

Then finish and publish the draft articles

Academic researchers

With the permission of the researcher of the project and the sponsor of the project, the Nutrition Research Center and the Research Deputy of the University-

Research Center for Nutrition Researchers

In-person attendance and obtaining relevant permissions _ Phone call